MaxCyte Reports Positive Financial Results for 2024
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a renowned company at the forefront of cell engineering, has shared exciting preliminary financial outcomes for its fourth quarter and the entire year of 2024. These results demonstrate steady growth in revenue and a stronger position in the rapidly evolving cell therapy industry.
Strong Core Revenue Growth
In the fourth quarter of 2024, MaxCyte expects its core revenue to range between $8.3 million and $8.5 million, marking a significant increase from $7.2 million in the same quarter of 2023. Moreover, the anticipated core revenue for the full year is projected between $32.2 million and $32.4 million, up from $29.8 million in 2023, which represents an impressive 8 to 9% growth. This positive trend reflects the growing demand for MaxCyte’s innovative cell-engineering technologies.
Financial Stability and Cash Reserves
As of December 31, 2024, MaxCyte expects its total cash, cash equivalents, and investments will amount to approximately $190 million. This figure is well above earlier projections, demonstrating the company's sound financial strategy and robust cash management, particularly in the face of evolving market conditions.
Improvements in the Cell Therapy Landscape
According to Maher Masoud, President and CEO of MaxCyte, the company's preliminary core revenue for 2024 aligns with the higher end of their revised guidance. He remarked on the improving conditions within the cell therapy sector and expressed confidence in MaxCyte's future opportunities. He highlighted that the number of SPL customers increased by six during the year, underscoring the company's expanding influence in the industry.
Innovation Driving Growth and Customer Expansion
MaxCyte has made significant progress in 2024, notably supporting the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA. This achievement positions MaxCyte among the leaders in this transformative field. The company continues to streamline operations while delivering healthy revenue growth, indicative of its commitment to innovation.
Looking Ahead to 2025
The preliminary results for the fourth quarter and full year 2024 are subject to change as MaxCyte completes its quarterly and year-end closing processes and prepares its audited financial statements. The finalized results are expected to be publicly released in March 2025 and will be included in MaxCyte's Annual Report on Form 10-K, providing investors and stakeholders with a comprehensive overview of the company’s performance.
About MaxCyte’s Technology and Commitment
MaxCyte has developed the ExPERT™ platform, based on its proprietary Flow Electroporation technology, which is designed to enhance cell therapy processes from discovery to commercialization. With over 25 years of expertise in the field, MaxCyte has established itself as a trusted partner in the cell-based medicine market. The ExPERT platform includes versatile instruments and a robust portfolio of processing assemblies, showcasing the company’s dedication to empowering partners and improving patient outcomes through advanced cell therapy solutions.
Frequently Asked Questions
What are the key financial results reported by MaxCyte?
MaxCyte reported core revenue of $8.3 to $8.5 million for Q4 2024, with total revenue for the year expected between $32.2 million and $32.4 million, marking a notable growth from the previous year.
How does MaxCyte plan to continue its growth?
MaxCyte plans to further expand its customer base, innovate within its product offerings, and continue supporting significant advancements in the cell therapy industry.
What technology does MaxCyte utilize for cell therapy?
MaxCyte uses its ExPERT™ platform, based on Flow Electroporation technology, which facilitates efficient cell engineering and supports various processes in the therapy development spectrum.
When will the finalized financial statements be available?
The finalized financial results for the fourth quarter and full year 2024 are expected to be released in March 2025 as part of MaxCyte's Annual Report on Form 10-K.
How can stakeholders learn more about MaxCyte?
Stakeholders can visit MaxCyte's official website for more information and updates about the company’s innovations and financial performance.
